Abstract
T-2 Toxin is a mycotoxin that induces toxemia characterized by numerous hematological and biochemical changes. We have previously shown that prostaglandin (PG) production in brain tissue is increased following T-2 toxin. The present study was designed in order to test the effect of dexamethasone on brain prostaglandins and survival of rats subjected to T-2 toxin. Furthermore, the effect of BW 755c, a dual inhibitor of the cyclooxygenase and lipoxygenase pathways of arachidonate metabolism, on the survival of rats exposed to T-2 toxin was also examined. The present study demonstrated that dexamethasone increases the survival of rats exposed to a highly lethal T-2 toxicosis. This effect was demonstrated at low as well as high doses and at different times after T-2 administration. Dexamethasone depressed PGE2 levels in the brain cortex 6 hr after T-2 toxin but abolished the reduction of PGE2 in brain cortex seen 24 hr after T-2. BW 755c had no consistent effect on the survival of rats in T-2 toxicosis. It is suggested that dexamethasone might be a useful therapeutic agent in T-2 toxicosis in animals and humans, but its mechanism of action remains obscure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
I. H.-C. Hsu, E. B. Smalley, F. M. Strong, and W. E. Ribelin. Appl. Microbiol. 24:684–690 (1972).
A. W. Hayes. Clin. Toxicol. 17:45–83 (1980).
C. A. Wilson, D. M. Everard, and R. Schoental. Toxicol. Lett. 10:35–40 (1982).
G. Feuerstein, D. S. Goldstein, P. W. Ramwell, R. L. Zerbe, W. E. Lux, Jr., A. I. Faden, and M. A. Bayorh. J. Pharmacol. Exp. Ther. 232:786–794 (1985).
R. M. Lorenzana, V. R. Beasley, W. B. Buck, A. W. Ghent, G. R. Lundeen, and R. H. Poppenga. Fund. Appl. Toxicol. 5:879–892 (1985).
E. Shohami and G. Feuerstein. T-2 toxemia and brain prostaglandins. Prostaglandins 31:307–319 (1986).
R. Y. Yarom, R. Sherman, I. More, R. Ginsburg, R. Borinski, and B. Yagen. Toxicol. Appl. Pharmacol. 75:60–68 (1984).
Y. Ueno. Fund. Appl. Toxicol. 4:S124–132 (1984).
G. J. Slotman, J. V. Quinn, K. W. Burchard, and D. S. Gann. Circ. Shock 16:395–404 (1985).
E. Shohami and J. Gross. J. Neurochem. 45:132–136 (1985).
J. R. Fletcher and P. W. Ramwell. Br. J. Pharmacol. 61:175–181 (1977).
W. C. Wise, J. A. Cook, P. V. Halushka, and D. R. Knapp. Circ. Res. 46:854–859 (1980).
G. Feuerstein, J. A. DiMicco, A. Ramu, and I. J. Kopin. J. Pharm. Pharmacol. 33:576–579 (1981).
H. Tremel, G. Strugala, W. Forth, and B. Fichtl. Arch. Toxicol. 57:74–75 (1985).
F. Hirata, E. Shiffmann, K. Venkatasubramanian, D. Salomon, and J. Axelrod. Proc. Natl. Acad. Sci. 77:2533–2636 (1980).
J. Weidenfeld, J. Lysy, and E. Shohami. J. Neurochem. 48:1351–1354 (1987).
O. Kempski, E. Shohami, D. von Lubitz, J. M. Hallenbeck, and G. Feuerstein. Stroke 18:111–119 (1987).
O. Lowry, N. Rosebrough, A. Farr, and R. Randall. J. Biol. Chem. 193:265–275 (1951).
W. M. Partridge. Physiol. Rev. 63:1481–1535 (1983).
E. Shohami, S. Globus and J. Weidenfeld. Exp. Brain Res. 61:87–90 (1985).
G. Feuerstein, J. A. Powell, A. T. Knower, and K. W. Hunter. J. Clin. Invest. 76:2134–2138 (1985).
U. Zor, T. Harel, Y. Ashkenazy, and S. Moshonov. Adv. Prostag. Thrombox. Leukot. Res. 16:269–286 (1986).
K. M. Mullane and S. Moncada. Prostaglandins 24:255–266 (1982).
G. Feuerstein, P. Leader, A.-L. Siren, and P. Braquet. Troxicol. Lett. 1987 (in press).
J. W. Holaday. Ann U. Rev. Pharmacol. Toxicol. 23:541–594 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shohami, E., Wisotsky, B., Kempski, O. et al. Therapeutic Effect of Dexamethasone in T-2 Toxicosis. Pharm Res 4, 527–530 (1987). https://doi.org/10.1023/A:1016444009179
Issue Date:
DOI: https://doi.org/10.1023/A:1016444009179